A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Dose-response Phase 2 Clinical Trial to Compare the Efficacy and Safety of Bronpass Tab. Versus Placebo in Patients With Stable COPD
Latest Information Update: 31 May 2024
At a glance
- Drugs HL 301 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Hanlim Pharmaceutical
- 31 May 2024 New trial record